Omega Therapeutics’ (OMGA) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Omega Therapeutics (NASDAQ:OMGA) in a research report released on Monday morning, RTT News reports. They currently have a $12.00 price target on the stock.

Several other brokerages have also recently weighed in on OMGA. HC Wainwright reaffirmed a buy rating and set a $12.00 price objective on shares of Omega Therapeutics in a research note on Tuesday, April 30th. Chardan Capital decreased their price target on Omega Therapeutics from $12.00 to $7.00 and set a buy rating on the stock in a research report on Monday, April 1st. Finally, Piper Sandler reaffirmed an overweight rating and set a $9.00 price target (down from $10.00) on shares of Omega Therapeutics in a report on Wednesday, April 3rd.

Omega Therapeutics Price Performance

Omega Therapeutics stock opened at $2.15 on Monday. The business has a 50 day simple moving average of $3.11 and a 200 day simple moving average of $2.98. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.35 and a quick ratio of 3.35. The company has a market capitalization of $118.30 million, a PE ratio of -1.19 and a beta of 1.99. Omega Therapeutics has a one year low of $1.30 and a one year high of $10.09.

Omega Therapeutics (NASDAQ:OMGA) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09. Omega Therapeutics had a negative return on equity of 110.41% and a negative net margin of 3,147.92%. The company had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $0.93 million. On average, sell-side analysts forecast that Omega Therapeutics will post -1.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Etfidea LLC bought a new stake in shares of Omega Therapeutics during the fourth quarter worth $39,000. Murphy Pohlad Asset Management LLC bought a new position in Omega Therapeutics in the fourth quarter valued at approximately $50,000. Finally, 683 Capital Management LLC grew its holdings in Omega Therapeutics by 7.0% during the 3rd quarter. 683 Capital Management LLC now owns 508,242 shares of the company’s stock worth $1,093,000 after acquiring an additional 33,242 shares during the period. Institutional investors own 97.47% of the company’s stock.

Omega Therapeutics Company Profile

Omega Therapeutics, Inc operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury.